StockNews.AISignal intelligence
Penumbra, Inc. · NYSE · Healthcare
Browse public PEN signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Boston Scientific is acquiring Penumbra for $14.5 billion. This acquisition strengthens BSX's cardiovascular portfolio. Penumbra’s shares increased by 14% due to the deal. BSX enters mechanical thrombectomy market through this acquisition. A transaction discussion is planned at 8:00 a.m. ET.
View signal analysisPEN reported Q1 2025 earnings that exceeded expectations significantly. Sales reached $324.1 million, beating forecasts and growing 16.3% year-over-year. Thrombectomy products revenue climbed 20.7%, with U.S. sales up 25.0%. Analysts raised price targets, indicating strong confidence in PEN's growth. Company forecasts reaffirmed despite macroeconomic considerations impacting other sectors.
View signal analysisPenumbra's stock showed a slight recovery after a correction. Analyst Steven Lichtman initiated Outperform rating with a $275 price target. Mid-teens sales and over 30% earnings growth forecasted for Penumbra. Mechanical thrombectomy market is expected to grow significantly in the U.S. International thrombectomy presents additional growth opportunities for Penumbra.
View signal analysis